KRAS and metabolic syndrome: In non recto-sigmoid cancers, high cholesterol was significantly associated with KRAS WT (OR 0.39, CI 0.15–0.97, p = 0.04), whilst there was a borderline association between MetS and KRAS mutation (OR 2.78, 95% CI 0.99–7.82, p = 0.05).